Literature DB >> 17420300

Gene therapy in the treatment of heart failure.

Hung Ly1, Yoshiaki Kawase, Ryuichi Yoneyama, Roger J Hajjar.   

Abstract

Heart failure is a major cause of morbidity and mortality in contemporary societies. Although progress in conventional treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore new and potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as heart failure. Advances in the understanding of the molecular basis of conditions such as these, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within reach of gene-based therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420300     DOI: 10.1152/physiol.00037.2006

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN: 1548-9221


  18 in total

Review 1.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 2.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 3.  Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Authors:  Shaina R Eckhouse; Jeffrey A Jones; Francis G Spinale
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

Review 4.  Cardiac gene therapy: are we there yet?

Authors:  P N Matkar; H Leong-Poi; K K Singh
Journal:  Gene Ther       Date:  2016-04-29       Impact factor: 5.250

5.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 6.  Current strategies for myocardial gene delivery.

Authors:  Michael G Katz; JaBaris D Swain; Catherine E Tomasulo; Marina Sumaroka; Anthony Fargnoli; Charles R Bridges
Journal:  J Mol Cell Cardiol       Date:  2010-09-15       Impact factor: 5.000

Review 7.  Advances in gene-based therapy for heart failure.

Authors:  Hung Q Ly; Yoshiaki Kawase; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2008-05-29       Impact factor: 4.132

8.  Intramyocardial injection of thioredoxin 2-expressing lentivirus alleviates myocardial ischemia-reperfusion injury in rats.

Authors:  Yanyan Li; Yin Xiang; Song Zhang; Yan Wang; Jie Yang; Wei Liu; Fengtai Xue
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

9.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

10.  In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice.

Authors:  Sergei Merkulov; Xiaoqin Chen; Margaret P Chandler; Julian E Stelzer
Journal:  Circ Heart Fail       Date:  2012-08-01       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.